13 December 2023
Latham & Watkins Advises Icosavax in US$1.1 Billion Acquisition by AstraZeneca
Advising firms
Deal team
33 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Daniel Rees Lead | Latham & Watkins LLP | Partner | corporate | Orange County |
| Matt Bush | Latham & Watkins LLP | Partner | corporate | San Diego |
| Cheston Larson | Latham & Watkins LLP | Partner | corporate | San Diego |
| Nima Movahedi | Latham & Watkins LLP | Associate | corporate | Not stated |
| Shannon Cheng | Latham & Watkins LLP | Associate | corporate | Not stated |
| Abby Timmons | Latham & Watkins LLP | Associate | corporate | Not stated |
| Tiana Baghdikian | Latham & Watkins LLP | Associate | corporate | Not stated |
| Lexi Zintel | Latham & Watkins LLP | Associate | corporate | Not stated |
| Nadia Patiño | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Derek Rogers | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Shelby Harrison | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | FDA/regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | FDA/regulatory | Bay Area |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA/regulatory | Washington, D.C. |
| Kiera Murphy | Latham & Watkins LLP | Associate | FDA/regulatory | San Diego |
| Eveline Van Keymeulen | Latham & Watkins LLP | Partner | ex-US regulatory | Paris |
| Jeanne Fabre | Latham & Watkins LLP | Associate | ex-US regulatory | Not stated |
| Chris Hazuka | Latham & Watkins LLP | Partner | IP | Bay Area |
| Robert Yeh | Latham & Watkins LLP | Associate | IP | San Diego |
| Michael Sweeney | Latham & Watkins LLP | Associate | IP | Los Angeles |
| Jennifer Barry | Latham & Watkins LLP | Partner | trademark | San Diego |
| Andrea Ramezan-Jackson | Latham & Watkins LLP | Partner | tax | Washington, D.C. |
| Nolon Blaylock | Latham & Watkins LLP | Associate | tax | Not stated |
| Holly Bauer | Latham & Watkins LLP | Partner | benefits and compensation | San Diego |
| Julie Voorhes | Latham & Watkins LLP | Associate | benefits and compensation | Not stated |
| Amanda Reeves | Latham & Watkins LLP | Partner | antitrust | Washington, D.C. |
| Patrick English | Latham & Watkins LLP | Counsel | antitrust | Not stated |
| Denver Dunn | Latham & Watkins LLP | Associate | antitrust | Denver |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Bay Area |
| Mitch Bennett | Latham & Watkins LLP | Associate | data privacy | Not stated |
| Oliver Mobasser | Latham & Watkins LLP | Associate | ex-US data privacy | London |
| Catherine Hein | Latham & Watkins LLP | Counsel | CFIUS | Washington, D.C. |
| Matthew Crawford | Latham & Watkins LLP | Associate | CFIUS | Boston |
Stated terms
- Stated value
- USD 1.10bn (US$1.1 Billion)
- What the figure measures
- Total transaction value
- Client
- Icosavax, Inc.Sell-side
- Counterparties
- AstraZeneca (Buy-side)